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Ocular diseases, such as, glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and retinitis pigmentosa
require drug management in order to prevent blindness and aﬀecting million of adults in USA and worldwide. There is an
increasing need to develop devices for drug delivery to address ocular diseases. This study focuses on the design, simulation, and
development of an implantable ocular drug delivery device consisting of micro-/nanochannels embedded between top and bottom
covers with a drug reservoir made from polydimethylsiloxane (PDMS) which is silicon-based organic and biodegradable polymer.
Several simulations were carried out with six diﬀerent micro-channel configurations in order to see the feasibility for ocular
drug delivery applications. Based on the results obtained, channel design of osmotic I and osmotic II satisfied the diﬀusion rates
required for ocular drug delivery. Finally, a prototype illustrating the three components of the drug delivery design is presented. In
the future, the device will be tested for its functionality and diﬀusion characteristics.
1. Introduction
New drugs for treating eye diseases have been developed
over the past decade and are very unique for each eye dis-
eases, such as, glaucoma, cataracts, and age-related macular
degeneration (AMD). It is estimated that 1.6 million adults
in the USA over the age of 50 and above suﬀer from age-
related macular degeneration and about 200,000 cases are
diagnosed annually. Worldwide, about 500,000 cases are
diagnosed annually [1]. Drugs currently utilized for AMD
are delivered via repeated intravitreal injections of the drug
into the eye. Risks of repeated intravitreal injections can
include intraocular infections (endophthalmitis), intraoc-
ular hemorrhage, and retinal detachment. Also, reducing
the frequency of dosing will clearly benefit the patient
by reducing the need for risky intravitreal injections and
improving the pharmacokinetics of the drug in the eye.
Eye disease in the posterior segment includes two diﬀerent
forms of AMD, such as, dry and wet. Approximately 90%
of patients with AMD have the Dry form shown in small
yellow and white deposits form made of proteins and waste
products. Wet ADM is caused by abnormal blood vessels
grow out of the retina followed by rapid vision loss. However,
these AMD diseases limit drug delivery in the retina region to
eye drops [2, 3].
The drug using a needle with syringe can be injected,
but it barely provides the right amount of dose and
over doses may cause more severe problems, such as,
swelling, fatigue, and damage photoreceptor molecules.
Furthermore, most drugs run out in a month and repeated
injections become necessary. Developing an implantable
drug delivery device will help reduce the costs and risks
associated with frequent injections and facilitate delivering
the drug in a controlled manner and in the required
amounts and improve therapeutic eﬃcacy and safety of
drugs.
Ocular diseases, such as, glaucoma, age-related macular
degeneration (AMD), diabetic retinopathy, and retinitis
pigmentosa require drug management in order to prevent
blindness [4]. These incurable diseases require lifelong treat-
ment through orally administered medications, intraocular
injections, and biodegradable implants. Drug delivery to
ocular tissue is very diﬃcult due to area and size limitations
in the eye. There are currently at least three major cate-
gories of ocular drug delivery systems as discussed in [1]:
biodegradable or nonbiodegradable, atypical implantable
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Table 1: Diﬀusion coeﬃcient of drugs for the AMD.
Drug Drug name (type)
Diﬀusion coeﬃcient
(cm2/s)
Average dosage
(nL/min)
Injection
amount/periods
References
Antiangiogenic
Macugen (pegaptanib
sodium)
3× 10−7 0.2083 3mg/10 days Swanson [12]
Lucentis
(ranibizumab)
2.08× 10−7 0.0124 0.5mg/month
Molokhia et al. [13]
Intravitrea Avastin
(bevacizumab)
1.25× 10−7 0.0289 1.25mg/month
Synthetic
corticosteroid
Fluocinolone
2.3× 10−7 0.0744 15mg/20 weeks Li et al. and Jaﬀe et al.
[14, 15]
Acetonide
Microchannels (silicon)
Depth: 5–100 µm,
Width = 50–500 µm
Drug reservoir
(PDMS)
Refill ring
(stainless steel)
D
rug/hydrogels
Bottom cover
(PDMS)
Figure 1: Proposed device design concept for ocular drug delivery.
pump systems, and implantable pump systems. Implantable
pump systems dispense drugs from an internal reservoir and
have the advantage of providing control over drug delivery
rate and volume. Several types of implantable pumps, such
as, infusion pumps, osmotic pumps, and peristaltic pumps
have been developed and used successfully for applications,
such as, insulin delivery but have been found to be unsuitable
for ocular drug delivery due to space limitations. Typical
implantable pump systems (hydrogel systems infused with
drug swell via intake of biological fluids for example)
minimize the drug volume required for treatment and
provide targeted delivery at a constant rate. However surgical
procedures are required to implant and replace these devices,
which may in turn contribute to additional side eﬀects.
Vitrasert and Retisert distributed by Bausch and Lomb
are commercially available examples of nonbiodegradable
systems. In these systems, the drug is released as a polymer
matrix infused with drug dissolves or the drug is distributed
from a nonbiodegradable reservoir. The disadvantages with
these systems include in vivo polymer degradation (and the
drug cannot be refilled) and the fact that drug delivery
is dependent upon a limited volume available within the
polymer.
Several models have been used to study the drug delivery
mechanisms [5–7]. Recently, a review of barriers to posterior
eye drug delivery and the challenges and opportunities were
discussed by Thrimawithana et al. [8]. Table 1 summarizes
various drugs, their diﬀusion coeﬃcients, the average dosage,
and the frequency to treat AMD diseases. Fick’s second
law of diﬀusion can be used to describe the transport
of drug into the eye using microchannels. As the drug
delivery device is implanted in the vitreous body of the eye,
usually the diﬀusion depends on the local concentration
rate between a drug reservoir and an aqueous humor.
The Fick’s second law of diﬀusion model can predict the
diﬀusion time of the local tissue concentration in the
eye following a variety of microchannel geometries for
ocular implantable delivery. The diﬀusion coeﬃcient of
drugs may vary based on the chemical properties and
internal structure as well as the molecular weight of the
drug.
Several Micro Electro-Mechanical System (MEMS)
devices, such as, microreservoirs and micropumps have been
fabricated to address the spatial constraints posed by ocular
drug delivery [1, 4]. Microreservoirs oﬀer maximum control
of drug delivery but cannot be refilled or reused, thereby rul-
ing out suitability for treating chronic eye conditions. Peri-
staltic micropumps provide targeted drug delivery through
active pumping but require considerable space to achieve
a desired volume of flow per minute. To overcome these
Journal of Drug Delivery 3
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Figure 2: An overview of the attachment of the implanted drug delivery device to the eye.
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Figure 4: Various microchannels patterns considered for design analysis and simulation.
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Figure 5: Simulation results of drug diﬀusion through a straight-
type microchannel configuration.
limitations, Lo et al. [9] recently developed a first generation
prototype polymer MEMS delivery device with a refillable
drug reservoir for treating ocular diseases. In addition to the
refillable drug reservoir, the device consists of a transcleral
cannula, check valve, and suture tabs. The device requires
surgical implantation underneath the conjunctiva and the
specified dose of medication is dispensed from the device
when the reservoir is mechanically activated by the patient’s
finger. This device has several advantages when compared
to existing systems including the following: the device is
refillable, requires only a single surgical intervention, and is
suitable for treating chronic ocular conditions; it is compact
and fits within the dimensions imposed by the ocular
orbit (<2mm thick). However, the device requires patient’s
intervention in dispersion of the drug.
In order to cater tomultiple scenarios in terms of amount
of drug delivery and constraints, alternate MEMS devices
might be of interest for treating ocular diseases. Nano-
/microchannel-based drug delivery technologies represent an
unprecedented opportunity to realize radically new devices
that would exploit the novel features of the nanochannels, in
which chip contains that drug reservoir with dose, provide
unique performance in terms of diﬀusion and kinetics
over existing technologies for drug delivery applications
[10].
This study focuses on the design, simulation, and
development of an implantable ocular drug delivery device.
A novel design concept consisting of micro/nanochannels
embedded between top and bottom covers with a drug
reservoir made from PDMS material was developed. Several
simulations were carried out with diﬀerent microchannel
configurations in order to see the feasibility for ocular
drug delivery applications. Finally, a prototype illustrat-
ing the three components of the drug delivery design is
presented.
2. Design and Development
2.1. Device Concept. A novel implantable device incorporat-
ing nanomicrochannels is proposed for ocular drug delivery.
As shown in Figure 1, the drug is stored in a reservoir
at one end of the device. Microchannels are coated with
hydrophilic coatings so that the drug from the reservoir
diﬀuses through the channels at specified/designed rate into
the eye eliminating the need for any controlled actuation.
Hydrogels (MIRAgel, MIRA Inc, Waltham, Mass), consisting
of poly (methyl acrylate-Co-2-Hydroxyethyl acrylyte) are
used as means to passively induce the drug delivery into
the microchannels so that the drug diﬀuses freely through
the channels and reaches the outlet for delivery. The
microchannel component with inlet/outlet reservoirs will
be enclosed in a PDMS case whose base is rounded to
match the curvature of the eye globe. The device is attached
securely to the sclera of the eye with fine 10–0 or 9–0 nylon
sutures. Ideally, the device would be surgically, transclerally
implanted in the vitreous space with an external thin curved
spherical surface flange that would be nearly flush with
the sclera and sutured in place (see Figure 2). The design
requirements for the proposed drug delivery device are as
follows:
(i) target overall volume is less than 280mm3;
(ii) diﬀusion rate is less than 0.07 nL/min;
(iii) target diﬀusion time period will be around 1 to 2
years;
(iv) kinetics: reliable diﬀusion coeﬃcient of drugs
through the microchannels;
(v) implantable: eliminate repeated injections for eﬀec-
tive treatment;
(vi) actuation: sustained release drug delivery methods.
2.2. Design Calculations. To illustrate the targeted volume
and rate of the drug delivery device, the following section
provides the details of calculations. It has been assumed
that drug-contained deionized water will be transported
through the microchannel from a reservoir. The corticos-
teroid fluocinolone acetonide has low solubility, so that
solution was made by dissolving 59mg of C24H30F2O6 in
deionized water of 50 μL (concentration in the device ≈
1.18mg/μL). We also assume that the concentration of drugs
in the water within the reservoir is around 1.18mg/cm3
and zero concentration within the retina region of the
eye. Using this value of concentration, we can estimate
the flux density of drug-contained water transport into
the retina region by molecular diﬀusion. However, in this
study, we assume that the diﬀusion coeﬃcient for typical
eye drug, which is the corticosteroid fluocinolone acetonide
in the deionized water, is equal to 2.3 × 10−7 cm2/s. The
concentration of drug in the reservoir is very large in
comparison to the concentration in the retina region. To
calculate the flux density, we use Fick’s Law (1), assuming
that the gradient of concentration with length is linear over
the microchannels path. The diﬀusive flux will be from the
reservoir to the eye, from a high concentration to a lower
concentration.
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Figure 6: Simulations of drug diﬀusion at 50 seconds through various microchannel configurations.
Fick’s first law, which relates the diﬀusive flux to the
concentration and is given as,
J = −D ∂φ
∂x
, (1)
where, J is the diﬀusion flux (g/cm2·s), D is the diﬀusion
coeﬃcient or diﬀusivity in dimension of cm2/s, and φ is the
concentration of drugs in the reservoir.
Using, the above values, we get
J = − 2.3 × 10−7 cm2/s · (1.18 g/cm3/0.8 cm)
= − 3.39 × 10−7 g/(cm2) · s.
(2)
Ignoring the diﬀusion direction, we calculate the flux
density of 3.39×10−7 g/cm2 · s and it can be used to calculate
the total mass flux of drug into the eye using (3) given below.
For example, if the straight microchannel has an inlet area
of 0.0005 cm2 with 12 separate pathways, then the total flux
into the eye is
Mtotal = J × A, (3)
where, A is a section area at the inlet.
Using the above values, we get
Mtotal = 3.39× 10−7 g/cm2 · s× 0.0005 cm2 × 60 s/minute
= 1.02× 10−8 g/min
≈ 1.04× 10−4 μL/min or 2.58mg/month
(total 12microchannels).
(4)
As per our specification, the drug delivery device contains
drug of 6mg in the deionized water, it can be continu-
ously used for around 11 to 12 months without refilling
injection.
2.3. Analysis and Simulation. In order to illustrate the proof-
of-concept, six diﬀerent micronanochannels are etched on
the silicon substrate using photolithography technology.
The overall dimensions of microchannels were within a
range of 1.5 ∼ 8.0mm in length, had a depth of 5 to
100 μm and a width may vary based on the geometry
of microchannels (50 ∼ 500μm) as shown in Figure 3.
The length of microchannels depends on the geometry of
diﬀusion channels. After the surface modification, such as,
6 Journal of Drug Delivery
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Figure 7: Diﬀusion rate for various microchannel configurations
considered.
oxygen plasma, the channels will provide various diﬀusion
rates in conjunction with the drug’s diﬀusion coeﬃcient.
The injection cannula (needle gauge # 25 or 32) on the
outlet of the device routes the drugs into the targeted region.
In order to understand the design characteristics of the
microchannels, we developed a coarse-grained representa-
tion of the microchannel geometry through computational
fluid dynamic analysis and optimization. Specifically, the role
of the microchannel geometry in passive free diﬀusion that
molecules can pass freely through the microchannel follow
concentration gradients is investigated and discussed. Finite
element (FE) analysis using ANSYS-Multiphysics module
was used to perform the design simulations. Six diﬀerent
microchannel geometries are developed to simulate the
thermal diﬀusivity as shown in Figure 4. Drug concentration
at the reservoir is assumed to be 1 kmol/m3 and drug con-
centration at the outlet to be 0 kmol/m3. This concentration
represents drug concentration in the eye. Drug diﬀusivity is
assumed to be the same as the synthetic corticosteroid fluoci-
nolone acetonide in deionized (DI) water (2.3× 10−7 cm2/s)
[8].
Simulation results of drug diﬀusion within the micro-
channels as a function of time and drug diﬀusion from
the drug reservoir revealed high-concentration areas to zero
drug concentration areas in the vitreous body. Since drug
consumption occurred at the blood vessel of a vitreous
body which can be approximated as zero, the amount of
diﬀusionmay vary with the concentration gradient, however,
a constant drug release rate can be obtained.
2.4. Fabrication. Master molds for both upper and bottom
layers of the reservoir are made of Acura 50 plastic (3D
system corp.) and constructed from 3D stereolithography
process using 3D Viper SLA system (3D system corp.).
PDMS [11] is mixed silicone elastomeric base and a curing
agent with a 10 : 1 ratio (SYLGARD 184, DOW CORNING)
and poured into the master molds. The PDMS is degassed
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Figure 8: Diﬀusion rate comparisons at diﬀerent times through the
microchannel designs (osmotic I and osmotic II) for ocular drug
delivery applications.
in a vacuum machine for 20 minutes (Durable medical
equipment Inc., Richmond, VA) and cured at room temper-
ature for 24 hours or 80◦C for 2 hours. The microchannel
geometries will be formed using soft lithography on the
4′′ silicon wafers after baking at 1000◦C for at least 10
hours to get at least 1 μm thickness of an oxides layer. The
wafers are vapor coated with hexamethyldisilazane (HMDS)
adhesion promoter. After the mask is completed, photoresist
(AZ ECI #3012, AZ Electronic Materials, Branchburg, NJ,
USA) is poured on the wafer around 2.5mL and spin coated
at 4000 rpm for 30 s (expected thickness less than 0.8 μm
layer), and then the wafer is baked at 90◦C for 1 minute.
After exposure, native oxide is removed with a 20% KOH
solution dip at 80◦C for 2 hours and 5 hours so that 100 and
250 μm etch depths for the microchannels will be achieved.
The final step of the wafer fabrication is to remove the oxide
by using a BOE etch. Lastly, the assorted microchannels will
be assembled to the PDMS reservoir and sealed using the
O2 plasma etching processes in accordance with 600mTorr
pressure and 20W power for 35 s.
3. Results and Discussion
Several simulations of drug diﬀusion rates from various
microchannel configurations were carried out. The result
of diﬀusion rate through typical straight microchannels is
shown in Figure 5. The length and width of the straight
microchannel for this simulation are 8mm and 500 μm. In
this simulation, we assumed that the drug diﬀuses from
the drug reservoir, as we discussed using Fick’s Law, which
states that molecules will diﬀuse out to an area of low
concentration from an area of high concentration through
microchannels. The movement of drug across a micro
channels in a manner driven solely by the concentration
gradient. Flow field reached at the end of the channel within
38 seconds. Fully developed flow, with sustainable diﬀusion
rates, occurred at approximately 150 seconds. The results of
Journal of Drug Delivery 7
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Figure 9: Illustration of drug diﬀusion through the osmotic II microchannel from the reservoir.
drug diﬀusion at 50 seconds through various microchannel
configurations considered are shown in Figure 6. It is inter-
esting to note that diﬀerent microchannel configurations will
give rise to diﬀerent diﬀusion rates. The drug diﬀusion rate as
a function of time for various microchannel configurations
is presented in Figure 7. It can be seen from Figure 7 that
each of the microchannel configurations exhibits diﬀerent
diﬀusion characteristics in terms of drug diﬀusion rates.
Initially, there is a drastic increase and after a certain time, the
diﬀusion rate is almost constant. If the drug was to be deliv-
ered at a constant rate over a one-hour period then the inlet
flux of straight microchannel would be 6.25 × 10−12 kmol/s.
Over the first second, there is a rapid increase of diﬀusion
rates up to approximately 1.24 × 10−13 kmol/s and then a
more gradual increase to approximately 6 × 10−12 kmol/s
after 105 seconds. Overall, each of the microchannel
configurations can deliver the drug at diﬀerent diﬀusion
rates.
Based on the results obtained through various micro-
channel configurations, the designs: osmotic I and osmotic
II best satisfied the diﬀusion rate specifications (less than
0.07 nL/min) for the developed ocular drug delivery device.
These results are presented in Figure 8. In order to demon-
strate the diﬀusion through the entire device, an analysis is
carried out using the osmotic II microchannel and the reser-
voir for 1500 seconds using ANSYS software. It is assumed
that the thermal conductivity and specific heat and density
were set as 0.6W·m−1·K−1, 4181.3 J/kg·K, and 850Kg/m3,
respectively, for simulating the diﬀusion through the device.
No thermal conduction is considered at the surrounding wall
+ +
Reservoir
(bottom)
Reservoir
(top)
Micro
channels
Figure 10: PDMS-fabricated drug delivery device concept.
of a device. The temperature of 120◦C at the inlet (center
top of reservoir) and 37.5◦C at the outlet is applied for this
simulation. The result of diﬀusion at various times is shown
in Figure 9. It can be seen from Figure 9 that a very slow
diﬀusion occurs most likely at the narrow channel paths.
This demonstrates that the developed microdevice is capable
of delivering the drug through the osmotic II microchannel
configuration.
The results obtained from the simulations confirmed
that the microchannels have the potential to be used
as a drug delivery system depending on desired flow
rates and drug concentrations. The proposed device can
produce a constant delivery rate, which is favorable to
the treatment of eye disease. Diﬀusion rates can be
customized to obtain eﬀective levels by varying height,
width, and length of microchannels. The overall fabricated
device is shown in Figure 10. Currently, the functionality
of the device is being explored and will be tested in
future.
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4. Conclusions
A microdevice concept for ocular drug delivery is proposed
in this paper. The design involves development of an
implantable device with micro-/nanochannels with top and
bottom covers. Six diﬀerent channel configurations were
developed and analyzed for their diﬀusion characteristics.
Based on the results obtained, channel design of osmotic
I and II satisfied the diﬀusion rates required for ocular
drug delivery. In addition to design simulations, the top
and bottom covers were fabricated from PDMS through
replica-molding techniques. The microchannels along with
top and bottom covers were all integrated into the device.
Currently, the device is being tested for its functionality
and diﬀusion characteristics. However, there are significant
challenges related to achieving reliable and sustainable
integration, bonding, diﬀusion of the drug into channels,
and controllability. The test evaluation will be performed
measuring the change in pH of a neutral solution using a
strong citric acid; it can be diﬀused out through the device.
These challenges are being addressed and will be presented in
our future work.
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